Given the serious charges against Dr. Kuklo–including fraud, forgery, and conducting an unapproved experiment on soldiers–the University of Washington’s failure to take action until a series of articles in The New York Times and pressure brought to bear by Sen. Charles Grassley, speaks volumes about a pervasive culture of arrogance in academia.
April 14: the FDA announced that Coast IRB "has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company’s ability to protect human subjects participating in clinical trials."
Another research scam uncovered by the GAO sting involved a "bogus IRB with a pet dog as its CEO."
The disconnect provides further evidence of how the prescription drug industry can shape, revise or even conceal negative research findings that affect the way doctors prescribe.
Study 15 was pivotal to AstraZeneca gaining FDA approval to market Seroquel. The burial of negative data suggests that the approval process was tainted and the drug's license should be recalled.
Two major cases of medical fraud have undermined patient safety and the integrity of the medico-scientific literature: But how each specialty responded is a study in contrast.
A news item in The New York Times: "Judges Plead Guilty in Payoffs for Jailing Youths" is more than just another example of corruption.
Pharmaceutical companies willingly settle court cases for hundreds of millions of dollars–even billions of dollars–to keep the truth about their drugs under seal.
A group of internal emails by Johnson & Johnson officials-mostly from officials in the company’s Risperdal marketing division-provide a bird’s eye view of collusion between the drug giant and Harvard’s leading child psychiatrist, Dr. Joseph Biederman, and one of Harvard’s premier teaching hospitals, Massachusetts General Hospital.
The deceptive marketing of antipsychotic drugs has prompted new advocacy group to launch "The Just Say "Know" to Prescription Drugs Campaign." Its goal is to get one million people to stop and reevaluate the medications they are taking.
What does the "Gillberg affair" suggest about the integrity of the data underlying the DAMP-ADHD hypothesis?
China is probably not a good place for the pharmaceutical industry–unless companies are willing to market their products without engaging in fraud…
